| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Sundeep Khosla | Q42164143 |
| P2093 | author name string | Merry Jo Oursler | |
| Matthew T Drake | |||
| Bart L Clarke | |||
| P2860 | cites work | Suppression of bone formation by osteoclastic expression of semaphorin 4D | Q24294299 |
| Molecular cloning of human cDNA for cathepsin K: novel cysteine proteinase predominantly expressed in bone | Q24309351 | ||
| Human osteoclast-poor osteopetrosis with hypogammaglobulinemia due to TNFRSF11A (RANK) mutations | Q24310432 | ||
| Sphingosine 1-phosphate as a regulator of osteoclast differentiation and osteoclast-osteoblast coupling | Q24319108 | ||
| Paternal uniparental disomy for chromosome 1 revealed by molecular analysis of a patient with pycnodysostosis | Q24538890 | ||
| Oncostatin M promotes bone formation independently of resorption when signaling through leukemia inhibitory factor receptor in mice | Q24642117 | ||
| Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research | Q26782621 | ||
| Coupling Signals between the Osteoclast and Osteoblast: How are Messages Transmitted between These Temporary Visitors to the Bone Surface? | Q28083559 | ||
| Structure and chromosomal assignment of the human cathepsin K gene | Q28117956 | ||
| Defects in TCIRG1 subunit of the vacuolar proton pump are responsible for a subset of human autosomal recessive osteopetrosis | Q28140437 | ||
| Mutations in the a3 subunit of the vacuolar H(+)-ATPase cause infantile malignant osteopetrosis | Q28143618 | ||
| Cancellous bone remodeling occurs in specialized compartments lined by cells expressing osteoblastic markers | Q74488802 | ||
| The collagenolytic activity of cathepsin K is unique among mammalian proteinases | Q77581104 | ||
| Study of immunoelectron microscopic localization of cathepsin K in osteoclasts and other bone cells in the mouse femur | Q77690449 | ||
| Surgical outcomes after treatment of fractures in femur and tibia in pycnodysostosis | Q79463027 | ||
| High bone mineral density in pycnodysostotic patients with a novel mutation in the propeptide of cathepsin K | Q79501815 | ||
| Molecular analysis and characterization of nine novel CTSK mutations in twelve patients affected by pycnodysostosis. Mutation in brief #961. Online | Q80068357 | ||
| Mechanisms of the anabolic effects of teriparatide on bone: insight from the treatment of a patient with pycnodysostosis | Q80779491 | ||
| Impaired bone resorption in cathepsin K-deficient mice is partially compensated for by enhanced osteoclastogenesis and increased expression of other proteases via an increased RANKL/OPG ratio | Q81304554 | ||
| Mandibular osteomyelitis and fracture successfully treated with vascularised iliac bone graft in a patient with pycnodysostosis | Q81399867 | ||
| Odanacatib reduces bone turnover and increases bone mass in the lumbar spine of skeletally mature ovariectomized rhesus monkeys | Q82663650 | ||
| Safety and efficacy of the cathepsin K inhibitor ONO-5334 in postmenopausal osteoporosis: the OCEAN study | Q83396466 | ||
| Odanacatib: location and timing are everything | Q83486054 | ||
| Evaluation of high-resolution peripheral quantitative computed tomography, finite element analysis and biomechanical testing in a pre-clinical model of osteoporosis: a study with odanacatib treatment in the ovariectomized adult rhesus monkey | Q83794040 | ||
| Morphea-like skin reactions in patients treated with the cathepsin K inhibitor balicatib | Q84100615 | ||
| An atypical subtrochanteric femoral fracture from pycnodysostosis: a lesson from nature | Q84193438 | ||
| Cathepsin K deficiency aggravates lung injury in hyperoxia-exposed newborn mice | Q84487317 | ||
| Odanacatib in the treatment of postmenopausal women with low bone mineral density: five years of continued therapy in a phase 2 study | Q84553314 | ||
| Cathepsin K inhibitors prevent bone loss in estrogen-deficient rabbits | Q84795050 | ||
| A case of osteosarcoma in a patient with pycnodysostosis | Q84903999 | ||
| A potential contribution of altered cathepsin L expression to the development of dermal fibrosis and vasculopathy in systemic sclerosis | Q86897492 | ||
| Bone turnover markers and pharmacokinetics of a new sustained-release formulation of the cathepsin K inhibitor, ONO-5334, in healthy post-menopausal women | Q87155621 | ||
| Continuous treatment with odanacatib for up to 8 years in postmenopausal women with low bone mineral density: a phase 2 study | Q87296824 | ||
| Effects of eight-month treatment with ONO-5334, a cathepsin K inhibitor, on bone metabolism, strength and microstructure in ovariectomized cynomolgus monkeys | Q87786472 | ||
| Coupling factors: how many candidates can there be? | Q87860942 | ||
| Osteoclast synthesis and secretion and activation of latent transforming growth factor beta | Q72058811 | ||
| Pycnodysostosis, with a familial chromosome anomaly | Q72756749 | ||
| Mineral density and bone strength are dissociated in long bones of rat osteopetrotic mutations | Q73069637 | ||
| The osteoclast-associated protease cathepsin K is expressed in human breast carcinoma | Q73931802 | ||
| Cathepsin K gene mutations and 1q21 haplotypes in at patients with pycnodysostosis in an outbred population | Q73949564 | ||
| 'Eph'ective signaling: forward, reverse and crosstalk | Q28179338 | ||
| Loss of the ClC-7 chloride channel leads to osteopetrosis in mice and man | Q28201425 | ||
| Albers-Schönberg disease (autosomal dominant osteopetrosis, type II) results from mutations in the ClCN7 chloride channel gene | Q28210464 | ||
| Structure, expression, and regulation of the major noncollagenous matrix proteins of bone | Q28247547 | ||
| The regulation of cathepsin K gene expression | Q28251189 | ||
| Increasing options for the treatment of osteoporosis | Q28254516 | ||
| Human cathepsin O2, a novel cysteine protease highly expressed in osteoclastomas and ovary molecular cloning, sequencing and tissue distribution | Q28290432 | ||
| The gene for pycnodysostosis maps to human chromosome 1cen–q21 | Q28296690 | ||
| Localization of cathepsin K in human osteoclasts by in situ hybridization and immunohistochemistry | Q28303355 | ||
| Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice | Q29547898 | ||
| A physical mechanism for coupling bone resorption and formation in adult human bone. | Q30485638 | ||
| Pycnodysostosis: clinical, radiologic, and endocrine evaluation and linear growth after growth hormone therapy | Q31939946 | ||
| Cathepsin K null mice show reduced adiposity during the rapid accumulation of fat stores | Q33292685 | ||
| Bone density, strength, and formation in adult cathepsin K (-/-) mice | Q33374935 | ||
| Osteoclasts control osteoblast chemotaxis via PDGF-BB/PDGF receptor beta signaling | Q33379619 | ||
| Cathepsin K analysis in a pycnodysostosis cohort: demographic, genotypic and phenotypic features | Q33615956 | ||
| Disruption of PTH receptor 1 in T cells protects against PTH-induced bone loss | Q33680465 | ||
| Characterization of novel cathepsin K mutations in the pro and mature polypeptide regions causing pycnodysostosis. | Q33843319 | ||
| T cells: critical bone regulators in health and disease | Q34079698 | ||
| Odanacatib treatment increases hip bone mass and cortical thickness by preserving endocortical bone formation and stimulating periosteal bone formation in the ovariectomized adult rhesus monkey | Q34082585 | ||
| The molecular basis of osteoclast differentiation and activation | Q34201145 | ||
| Factors and mechanisms involved in the coupling from bone resorption to formation: how osteoclasts talk to osteoblasts | Q34219161 | ||
| Osteopetrosis | Q34380528 | ||
| Chemorepulsion by blood S1P regulates osteoclast precursor mobilization and bone remodeling in vivo | Q34420830 | ||
| Disruption of the cathepsin K gene reduces atherosclerosis progression and induces plaque fibrosis but accelerates macrophage foam cell formation | Q34478046 | ||
| Novel mutations of the cathepsin K gene in patients with pycnodysostosis and their characterization | Q34506716 | ||
| Linking osteopetrosis and pycnodysostosis: regulation of cathepsin K expression by the microphthalmia transcription factor family | Q34514934 | ||
| THE MALADY OF TOULOUSE-LAUTREC. | Q34541226 | ||
| Periosteal remodeling at the femoral neck in nonhuman primates | Q34543466 | ||
| Novel pycnodysostosis mouse model uncovers cathepsin K function as a potential regulator of osteoclast apoptosis and senescence | Q34573852 | ||
| Modulation of type beta transforming growth factor activity in bone cultures by osteotropic hormones | Q34610078 | ||
| Near normalization of adult height and body proportions by growth hormone in pycnodysostosis | Q34618386 | ||
| Molecular and clinical analysis in a series of patients with Pyknodysostosis reveals some uncommon phenotypic findings | Q34769776 | ||
| Effect of odanacatib on bone turnover markers, bone density and geometry of the spine and hip of ovariectomized monkeys: a head-to-head comparison with alendronate | Q34786147 | ||
| Coupling the activities of bone formation and resorption: a multitude of signals within the basic multicellular unit | Q37506724 | ||
| Cathepsin K knockout alleviates pressure overload-induced cardiac hypertrophy | Q37593416 | ||
| Cathepsin K in the immunohistochemical diagnosis of melanocytic lesions | Q37676779 | ||
| Osteoclast Activity and Subtypes as a Function of Physiology and Pathology—Implications for Future Treatments of Osteoporosis | Q37790176 | ||
| Fracture management in pycnodysostosis: 27 years of follow-up | Q37849733 | ||
| Cysteine proteases: mode of action and role in epidermal differentiation | Q38076304 | ||
| Osteoclast-derived coupling factors in bone remodeling | Q38108750 | ||
| Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research | Q38109833 | ||
| Cysteine cathepsins and extracellular matrix degradation. | Q38200374 | ||
| Clinical and radiographic maxillofacial features of pycnodysostosis | Q38206201 | ||
| The reversal phase of the bone-remodeling cycle: cellular prerequisites for coupling resorption and formation | Q38239680 | ||
| The clinical spectrum and pathophysiology of skeletal complications in lysosomal storage disorders | Q38490017 | ||
| The effect of consanguinity on the reproductive wastage in the Turkish population. | Q39283377 | ||
| Afamin secreted from nonresorbing osteoclasts acts as a chemokine for preosteoblasts via the Akt-signaling pathway | Q39322224 | ||
| A specific subtype of osteoclasts secretes factors inducing nodule formation by osteoblasts. | Q39327208 | ||
| Local regulators of skeletal growth: a perspective | Q39498262 | ||
| Normal and pathological remodeling of human trabecular bone: three dimensional reconstruction of the remodeling sequence in normals and in metabolic bone disease | Q39748604 | ||
| Upregulation of cathepsin S in psoriatic keratinocytes | Q39784577 | ||
| Treatment of osteoporoses by manipulation of coherent bone cell populations | Q39825655 | ||
| Novel mutation and white matter involvement in an Indian child with pycnodysostosis | Q40228038 | ||
| Lysosomotropism of basic cathepsin K inhibitors contributes to increased cellular potencies against off-target cathepsins and reduced functional selectivity | Q40348633 | ||
| RANK ligand and interferon gamma differentially regulate cathepsin gene expression in pre-osteoclastic cells. | Q40461557 | ||
| Identification of cathepsin K as a novel marker of adiposity in white adipose tissue. | Q40661967 | ||
| Platelet-derived growth factor BB secreted from osteoclasts acts as an osteoblastogenesis inhibitory factor | Q40754782 | ||
| Overexpression of cathepsin K in mice decreases collagen deposition and lung resistance in response to bleomycin-induced pulmonary fibrosis | Q41171992 | ||
| Osteoprotection by semaphorin 3A. | Q41791623 | ||
| Pycnodysostosis with novel gene mutation and severe obstructive sleep apnoea: management of a complex case | Q41893850 | ||
| Human cathepsin O2, a matrix protein-degrading cysteine protease expressed in osteoclasts. Functional expression of human cathepsin O2 in Spodoptera frugiperda and characterization of the enzyme | Q42064898 | ||
| A patient with pycnodysostosis presenting with seizures and porencephalic cysts | Q42113908 | ||
| Cathepsin D expression in chronic plaque psoriasis: an immunohistochemical study. | Q42494725 | ||
| Bone density, turnover, and estimated strength in postmenopausal women treated with odanacatib: a randomized trial | Q42713320 | ||
| The cathepsin K inhibitor odanacatib suppresses bone resorption in women with breast cancer and established bone metastases: results of a 4-week, double-blind, randomized, controlled trial | Q42781348 | ||
| Papilledema from craniosynostosis in pycnodysostosis | Q42822009 | ||
| A novel missense mutation in cathepsin K (CTSK) gene in a consanguineous Pakistani family with pycnodysostosis | Q43122647 | ||
| The resorptive apparatus of osteoclasts supports lysosomotropism and increases potency of basic versus non-basic inhibitors of cathepsin K. | Q43185375 | ||
| Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density | Q43252754 | ||
| Treatment with a potent cathepsin K inhibitor preserves cortical and trabecular bone mass in ovariectomized monkeys | Q43274929 | ||
| Understanding coupling between bone resorption and formation: are reversal cells the missing link? | Q43405568 | ||
| High-resolution peripheral quantitative computed tomography and finite element analysis of bone strength at the distal radius in ovariectomized adult rhesus monkey demonstrate efficacy of odanacatib and differentiation from alendronate | Q43444356 | ||
| Human osteoclast cathepsin K is processed intracellularly prior to attachment and bone resorption | Q43558401 | ||
| Effects of odanacatib on BMD and safety in the treatment of osteoporosis in postmenopausal women previously treated with alendronate: a randomized placebo-controlled trial | Q43733116 | ||
| A novel mutation (R122Q) in the cathepsin K gene in a Chinese child with Pyknodysostosis | Q43797875 | ||
| Familial pycnodysostosis: identification of a novel mutation in the CTSK gene (cathepsin K) | Q44018132 | ||
| Differential effects of androgens and estrogens on bone turnover in normal men. | Q44273273 | ||
| Cathepsin K mRNA and protein expression in prostate cancer progression | Q44303172 | ||
| Clinical, genetic, and cellular analysis of 49 osteopetrotic patients: implications for diagnosis and treatment. | Q36927212 | ||
| Cysteine cathepsins: cellular roadmap to different functions | Q36934250 | ||
| Regulation of bone formation by osteoclasts involves Wnt/BMP signaling and the chemokine sphingosine-1-phosphate. | Q37015968 | ||
| Cathepsin K inhibitors: a novel target for osteoporosis therapy | Q37029906 | ||
| Odanacatib in postmenopausal women with low bone mineral density: a review of current clinical evidence | Q37058788 | ||
| Osteoclast-secreted CTHRC1 in the coupling of bone resorption to formation | Q37123948 | ||
| Drug-induced morphea: report of a case induced by balicatib and review of the literature | Q37138210 | ||
| TGF-β induces Wnt10b in osteoclasts from female mice to enhance coupling to osteoblasts | Q37181921 | ||
| Ablation of cathepsin k activity in the young mouse causes hypermineralization of long bone and growth plates | Q37187086 | ||
| Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men | Q37272054 | ||
| TGF-beta1-induced migration of bone mesenchymal stem cells couples bone resorption with formation | Q37307155 | ||
| Expression of the elastolytic cathepsins S and K in human atheroma and regulation of their production in smooth muscle cells | Q37384330 | ||
| Molecular mechanisms in coupling of bone formation to resorption. | Q37385000 | ||
| Inhibition of osteoblastic bone formation by nuclear factor-kappaB. | Q37401772 | ||
| Cathepsin K inhibitors increase distal femoral bone mineral density in rapidly growing rabbits | Q37427459 | ||
| Exome sequencing identifies CTSK mutations in patients originally diagnosed as intermediate osteopetrosis. | Q37453562 | ||
| EphrinB2 regulation by PTH and PTHrP revealed by molecular profiling in differentiating osteoblasts | Q34796085 | ||
| Defective growth hormone secretion in children with pycnodysostosis and improved linear growth after growth hormone treatment | Q34799586 | ||
| Thyroid functions of mouse cathepsins B, K, and L. | Q35019251 | ||
| Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacatib Fracture Trial | Q35033184 | ||
| Clinical and animal research findings in pycnodysostosis and gene mutations of cathepsin K from 1996 to 2011 | Q35040136 | ||
| ONO-5334, a cathepsin K inhibitor, improves bone strength by preferentially increasing cortical bone mass in ovariectomized rats | Q35062434 | ||
| Pivotal role of cathepsin K in lung fibrosis | Q35098381 | ||
| Inhibition of cathepsin K increases modeling-based bone formation, and improves cortical dimension and strength in adult ovariectomized monkeys | Q35109866 | ||
| Odanacatib treatment affects trabecular and cortical bone in the femur of postmenopausal women: results of a two-year placebo-controlled trial | Q35181789 | ||
| A small molecule, odanacatib, inhibits inflammation and bone loss caused by endodontic disease | Q35187625 | ||
| Increased fracture callus mineralization and strength in cathepsin K knockout mice | Q35188085 | ||
| Cell line IDG-SW3 replicates osteoblast-to-late-osteocyte differentiation in vitro and accelerates bone formation in vivo | Q35332147 | ||
| Odanacatib: a review of its potential in the management of osteoporosis in postmenopausal women | Q35589110 | ||
| A 2003 update of bone physiology and Wolff's Law for clinicians | Q35706996 | ||
| Decreased bone turnover and deterioration of bone structure in two cases of pycnodysostosis | Q35740740 | ||
| Silencing of parathyroid hormone (PTH) receptor 1 in T cells blunts the bone anabolic activity of PTH | Q35849800 | ||
| Characterization of circulating osteoblast lineage cells in humans | Q35894606 | ||
| Osteoclast-derived activity in the coupling of bone formation to resorption. | Q36032429 | ||
| Estrogen and the skeleton | Q36179747 | ||
| Matrix IGF-1 maintains bone mass by activation of mTOR in mesenchymal stem cells | Q36223256 | ||
| Odanacatib, A Cathepsin K-Specific Inhibitor, Inhibits Inflammation and Bone Loss Caused by Periodontal Diseases | Q36289023 | ||
| Mice, double deficient in lysosomal serine carboxypeptidases Scpep1 and Cathepsin A develop the hyperproliferative vesicular corneal dystrophy and hypertrophic skin thickenings. | Q36289890 | ||
| Decreased c-Src expression enhances osteoblast differentiation and bone formation | Q36366926 | ||
| Building bone to reverse osteoporosis and repair fractures | Q36407024 | ||
| Intermittent parathyroid hormone administration converts quiescent lining cells to active osteoblasts | Q36486277 | ||
| Cathepsin K knockout mitigates high-fat diet-induced cardiac hypertrophy and contractile dysfunction | Q36560578 | ||
| Osteoclast-specific cathepsin K deletion stimulates S1P-dependent bone formation | Q36580426 | ||
| Sphingosine 1-phosphate (S1P) receptors 1 and 2 coordinately induce mesenchymal cell migration through S1P activation of complementary kinase pathways | Q36636026 | ||
| Tartrate-resistant acid phosphatase 5b (TRACP 5b) as a marker of bone resorption. | Q36641421 | ||
| The molecular understanding of osteoclast differentiation | Q36650749 | ||
| Insights into material and structural basis of bone fragility from diseases associated with fractures: how determinants of the biomechanical properties of bone are compromised by disease. | Q36697904 | ||
| Are nonresorbing osteoclasts sources of bone anabolic activity? | Q36709511 | ||
| Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice | Q36791739 | ||
| Odanacatib, a selective cathepsin K inhibitor to treat osteoporosis: safety, tolerability, pharmacokinetics and pharmacodynamics--results from single oral dose studies in healthy volunteers. | Q36792968 | ||
| Bone resorption and formation on the periosteal envelope of the ilium: a histomorphometric study in healthy women | Q44783413 | ||
| Osteoclast-derived serum tartrate-resistant acid phosphatase 5b in Albers-Schonberg disease (type II autosomal dominant osteopetrosis). | Q44796989 | ||
| Osteoclast deficiency results in disorganized matrix, reduced mineralization, and abnormal osteoblast behavior in developing bone | Q45018962 | ||
| Increased presence of capillaries next to remodeling sites in adult human cancellous bone. | Q45881370 | ||
| Expression and regulation of cathepsin K in skin fibroblasts. | Q45996302 | ||
| Effect of the cathepsin K inhibitor odanacatib on bone resorption biomarkers in healthy postmenopausal women: two double-blind, randomized, placebo-controlled phase I studies. | Q46022677 | ||
| Molecular analysis of a novel cathepsin K gene mutation in a Chinese child with pycnodysostosis | Q46122811 | ||
| Odanacatib Restores Trabecular Bone of Skeletally Mature Female Rabbits With Osteopenia but Induces Brittleness of Cortical Bone: A Comparative Study of the Investigational Drug With PTH, Estrogen, and Alendronate | Q46279925 | ||
| Odanacatib increases mineralized callus during fracture healing in a rabbit ulnar osteotomy model. | Q46280547 | ||
| Human osteoblasts produce cathepsin K. | Q46282719 | ||
| Reduced osteoblastic population and defective mineralization in osteopetrotic (op/op) mice | Q46283054 | ||
| Effects of Odanacatib on bone mineralization density distribution in thoracic spine and femora of ovariectomized adult rhesus monkeys: a quantitative backscattered electron imaging study. | Q46289368 | ||
| Cathepsins B, K, and L are regulated by a defined collagen type II peptide via activation of classical protein kinase C and p38 MAP kinase in articular chondrocytes | Q46908223 | ||
| Effect of cathepsin k inhibitor basicity on in vivo off-target activities | Q46947736 | ||
| Response of biochemical markers of bone turnover to hormone replacement therapy: impact of biological variability. | Q47857557 | ||
| Effect of ONO-5334 on bone mineral density and biochemical markers of bone turnover in postmenopausal osteoporosis: 2-year results from the OCEAN study. | Q47966083 | ||
| Plexin-A1 and its interaction with DAP12 in immune responses and bone homeostasis | Q50335578 | ||
| Increased expression and activation of cathepsin K in human osteoarthritic cartilage and synovial tissues | Q50438836 | ||
| Loss of osteocyte integrity in association with microdamage and bone remodeling after fatigue in vivo. | Q50514494 | ||
| Sema3A regulates bone-mass accrual through sensory innervations. | Q50745844 | ||
| A novel mutation in two families with pycnodysostosis. | Q50978170 | ||
| Expression of cathepsin K and tartrate-resistant acid phosphatase is not confined to osteoclasts but is a general feature of multinucleated giant cells: systematic analysis. | Q50993445 | ||
| Atypical femur fractures in a patient with pycnodysostosis: a case report. | Q51019184 | ||
| Odanacatib, a selective cathepsin K inhibitor, demonstrates comparable pharmacodynamics and pharmacokinetics in older men and postmenopausal women. | Q51182200 | ||
| Effect of the cathepsin K inhibitor odanacatib administered once weekly on bone mineral density in Japanese patients with osteoporosis--a double-blind, randomized, dose-finding study. | Q51239894 | ||
| Balicatib, a cathepsin K inhibitor, stimulates periosteal bone formation in monkeys. | Q51506177 | ||
| A highly potent inhibitor of cathepsin K (relacatib) reduces biomarkers of bone resorption both in vitro and in an acute model of elevated bone turnover in vivo in monkeys. | Q51787069 | ||
| Mice lacking cathepsin K maintain bone remodeling but develop bone fragility despite high bone mass. | Q51801651 | ||
| Cathepsin K expression in human lung. | Q52167712 | ||
| Regulation of osteoclast differentiation and function by receptor activator of NFkB ligand and osteoprotegerin. | Q53959402 | ||
| Determination of bone markers in pycnodysostosis: effects of cathepsin K deficiency on bone matrix degradation. | Q54071347 | ||
| Ultrastructural investigations of bone resorptive cells in two types of autosomal dominant osteopetrosis. | Q54227754 | ||
| Novel CTSK mutation resulting in an entire exon 2 skipping in a Thai girl with pycnodysostosis. | Q54239113 | ||
| Mechanical loading stimulates bone formation by reactivation of bone lining cells in 13-week-old rats. | Q54601079 | ||
| Circulating osteoblast-lineage cells in humans. | Q54664097 | ||
| Non-resorbing osteoclasts induce migration and osteogenic differentiation of mesenchymal stem cells. | Q54706728 | ||
| Differentiation potential of a mouse bone marrow stromal cell line. | Q54722455 | ||
| Craniosynostosis in pycnodysostosis: broadening the spectrum of the cranial flat bone abnormalities | Q56331110 | ||
| Cardiotrophin-1 Is an Osteoclast-Derived Stimulus of Bone Formation Required for Normal Bone Remodeling | Q57265515 | ||
| Cathepsin K Knockout Mice Develop Osteopetrosis Due to a Deficit in Matrix Degradation but Not Demineralization | Q57272396 | ||
| Bidirectional ephrinB2-EphB4 signaling controls bone homeostasis | Q57675131 | ||
| Bisphosphonate-Associated Osteonecrosis of the Jaw: Report of a Task Force of the American Society for Bone and Mineral Research | Q58216587 | ||
| Odanacatib in the treatment of postmenopausal women with low bone mineral density: Three-year continued therapy and resolution of effect | Q58970743 | ||
| Suggested Sequential Mode of Control of Changes in Cell Behaviour in Adult Bone Remodelling | Q59076842 | ||
| Activation of the bone-derived latent TGF beta complex by isolated osteoclasts | Q61961261 | ||
| Upper airway surgery of obstructive sleep apnea in pycnodysostosis: Case report and literature review | Q62065401 | ||
| The coupling of bone formation to bone resorption: a critical analysis of the concept and of its relevance to the pathogenesis of osteoporosis | Q70459032 | ||
| Pycnodysostosis: refined linkage and radiation hybrid analyses reduce the critical region to 2 cM at 1q21 and map two candidate genes | Q71235368 | ||
| Evidence that intermittent treatment with parathyroid hormone increases bone formation in adult rats by activation of bone lining cells | Q71940337 | ||
| P921 | main subject | lessons learned | Q1673259 |
| osteoporosis | Q165328 | ||
| P577 | publication date | 2017-06-23 | |
| P1433 | published in | Endocrine Reviews | Q3054007 |
| P1476 | title | Cathepsin K Inhibitors for Osteoporosis: Biology, Potential Clinical Utility, and Lessons Learned |
| Q47229748 | A composite docking approach for the identification and characterization of ectosteric inhibitors of cathepsin K. |
| Q92198455 | A small molecular inhibitor of LRRK1 identified by homology modeling and virtual screening suppresses osteoclast function, but not osteoclast differentiation, in vitro |
| Q99239630 | Cathepsin S as a potential therapeutic target for chronic pain |
| Q91825707 | Cigarette Smoke Extract Activates Tartrate-Resistant Acid Phosphatase-Positive Macrophage |
| Q94672407 | Coumarin as a structural component of substrates and probes for serine and cysteine proteases |
| Q90263630 | Coupling factors involved in preserving bone balance |
| Q92496051 | Fluid Shear Stress Suppresses Osteoclast Differentiation in RAW264.7 Cells through Extracellular Signal-Regulated Kinase 5 (ERK5) Signaling Pathway |
| Q90451142 | Friend or Foe? Essential Roles of Osteoclast in Maintaining Skeletal Health |
| Q93049353 | High Concentrations of Polyelectrolyte Complex Nanoparticles Decrease Activity of Osteoclasts |
| Q92860146 | In silico Guided Drug Repurposing: Discovery of New Competitive and Non-competitive Inhibitors of Falcipain-2 |
| Q90205467 | MicroRNA-29a represses osteoclast formation and protects against osteoporosis by regulating PCAF-mediated RANKL and CXCL12 |
| Q92553500 | Novel broad-spectrum activity-based probes to profile malarial cysteine proteases |
| Q91060161 | Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study |
| Q89555393 | Osteoclast-mediated bone resorption is controlled by a compensatory network of secreted and membrane-tethered metalloproteinases |
| Q89990612 | Peptidomimetic Vinyl Heterocyclic Inhibitors of Cruzain Effect Antitrypanosomal Activity |
| Q91726950 | Periprosthetic Osteolysis: Mechanisms, Prevention and Treatment |
| Q88815365 | Preservation of type H vessels and osteoblasts by enhanced preosteoclast platelet-derived growth factor type BB attenuates glucocorticoid-induced osteoporosis in growing mice |
| Q57022956 | Proteases: Pivot Points in Functional Proteomics |
| Q49488112 | Pycnodysostosis with novel gene mutation and sporadic medullary thyroid carcinoma: A case report |
| Q58593482 | Regulatory Aspects of the Development of Drugs for Metabolic Bone Diseases - FDA and EMA Perspective |
| Q64096815 | Relationship between senile osteoporosis and cardiovascular and cerebrovascular diseases |
| Q98466637 | Species-Specificity of Transcriptional Regulation and the Response to Lipopolysaccharide in Mammalian Macrophages |
| Q48348300 | Tanshinones that selectively block the collagenase activity of cathepsin K provide a novel class of ectosteric antiresorptive agents for bone. |
| Q64234280 | The Alkyne Moiety as a Latent Electrophile in Irreversible Covalent Small Molecule Inhibitors of Cathepsin K |
| Q90748781 | Treadmill Running in Established Phase Arthritis Inhibits Joint Destruction in Rat Rheumatoid Arthritis Models |
Search more.